Patent intelligence · US
US 6884888
Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
Patent details — US 6884888
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 26, 2005
- Expiration
- Apr 21, 2025
- Applicant
- Teva Gyogyszergyar Reszvenytarsasag
- Claims
- 24
- CPC classes
- A61P, A61P25/20, A61P25/22
Quick answer
US 6884888 (Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)) is held by Teva Gyogyszergyar Reszvenytarsasag. Status: expired. Granted Apr 26, 2005. Expires Apr 21, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Teva Gyogyszergyar Reszvenytarsasag
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61P, A61P25/20, A61P25/22
More from Teva Gyogyszergyar Reszvenytarsasag
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 6884888?
US 6884888 (Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)) is held by Teva Gyogyszergyar Reszvenytarsasag. Status: expired. Granted Apr 26, 2005. Expires Apr 21, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6884888?
Teva Gyogyszergyar Reszvenytarsasag is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 6884888 expire?
Our index shows an expiration date of Apr 21, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.